CYLERT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jan 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLERT is an oral tablet NDA approved in 1975 by Abbott for an undisclosed indication. The drug's mechanism of action, pharmacologic class, and specific clinical use are not documented in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely in maintenance or transition mode with minimal growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect CYLERT's legacy status and diminishing commercial priority. Roles available would focus on defending existing revenue, managing generic transition, and cost containment rather than growth or innovation.
Brand ManagerProduct Manager
Worked on CYLERT at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.